wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 12. no 2. June 2007  

 Diagnostics and treatment of allergy
Allergy vaccines - chances to improve safety

The safety aspects of specific immunotherapy (SIT) are still controversial and the procedure has some limitations. The probability of SIT side effects can be significantly reduced by appropriate standardisation of therapeutic allergens, introduction of specific allergoids, new adjuvants, recombinant allergens, synthetic peptides with main epitopes of major allergens, and developing new methods of immunotherapy.
The application of varying arbitrary units or producers' own units may be confusing, render vaccines assessment difficult, lead to ambiguous results of clinical studies, scientific controversies and therapeutic problems during immunotherapy. All allergology societies recommend allergy vaccine standardisation to avoid the above mentioned pitfalls.
The implementation of molecular biology allows us to understand the structure of many allergens and improve the quality of therapeutic preparations. Changing the tertiary structure of allergens or partial deletion of B-cell epitopes allows for the synthesis of allergoids, or chemically modified allergens. The recombinant allergens, which retain all the features of allergoids, may constitute the basis for strictly defined chemical modifications.
The production of allergen vaccines based on new and improved adjuvants is another option for safe SIT. Adjuvants strengthen vaccine immunogenicity without enhancing IgE-mediated reactions. Oligonucleotids (ODN CpG) bound to allergen proteins are the future of immunotherapy.

keywords: szczepionki alergenowe, standaryzacja, alergoidy, alergeny rekombinowane, adiuwanty, allergen vaccines, standardisation, allergoids, recombinant allergens, adjuvants

pages: from 73 to 80

estimated time of download (396 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.